Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Nov 15;72(22):5663-8.
doi: 10.1158/0008-5472.CAN-12-1527. Epub 2012 Nov 8.

Realizing the clinical potential of cancer nanotechnology by minimizing toxicologic and targeted delivery concerns

Sanjay Singh  1 , Arati Sharma, Gavin P Robertson
Affiliations
Review

Realizing the clinical potential of cancer nanotechnology by minimizing toxicologic and targeted delivery concerns

Sanjay Singh et al. Cancer Res. .

Abstract

Nanotechnology has the potential to make smart drugs that would be capable of targeting cancer but not normal cells and to load combinations of cooperating agents into a single nanosized particle to more effectively treat this disease. However, to realize the full potential of this technology, the negative aspects associated with these nanoparticles need to be overcome. This review discusses concerns in the field limiting realization of the full clinical potential of this technology, which are toxicity and targeted delivery. Strategies to overcome these hurdles are also reviewed, which could lead to attainment of the full clinical potential of this exciting technology.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Design of an ideal nanoparticle system. A, depicts the nanomaterial-associated toxicity and possible prevention strategies. B, focuses on major limitations and potential methods to improve nanoparticle-based targeted drug delivery approaches. The proposed nanoparticle system would exhibit minimum toxicity and maximum cancer therapeutic efficacy, which will improve the clinical potential of cancer nanotechnology.
See this image and copyright information in PMC

References

    1. Langer R. Drug delivery and targeting. Nature. 1998;392:5–10. - PubMed
    1. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov. 2003;2:347–60. - PubMed
    1. McNeil SE. Nanotechnology for the biologist. J Leukoc Biol. 2005;78:585–94. - PubMed
    1. Grodzinski P, Silver M, Molnar LK. Nanotechnology for cancer diagnostics: promises and challenges. Expert Rev Mol Diagn. 2006;6:307–18. - PubMed
    1. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med. 2002;53:615–27. - PubMed

Publication types

MeSH terms

Substances